Clinical trial
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130
Study timeline
Study start (actual)2022-11-30Date precision: day
Registry last updated2026-09-01
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Melanomaunresolved
Gliomaunresolved
Thyroid Cancerunresolved
Non-Small Cell Lung Cancerunresolved
Malignant Neoplasmsunresolved
Brain Neoplasmsunresolved
Advanced or Metastatic Solid Tumorsunresolved
HGGunresolved
LGGunresolved
Low Grade Gliomaunresolved
High Grade Gliomaunresolved
Differentiated Thyroid Cancerunresolved
NSCLC (Non-small Cell Lung Cancer)unresolved
Interventions
PF-07799544DRUG
PF-07799933DRUG
Sponsors & collaborators
Pfizerlead sponsor
Mapped research locations
New YorkNew York, United States5Los AngelesCalifornia, United States4San FranciscoCalifornia, United States3BirminghamAlabama, United States3TampaFlorida, United States3BostonMassachusetts, United States2TorontoOntario, Canada2SeattleWashington, United States2ClevelandOhio, United States2PortlandOregon, United States2MontrealQuebec, Canada2DetroitMichigan, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05538130 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.